Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

Inclusion Criteria: 1. Voluntarily sign the informed consent form; 2. 18-75 years old; 3. Women in any menstrual state, premenopausal or perimenopausal patients need to receive luteinizing hormone releasing hormone(LHRH) analogue; 4. Eastern Cooperative Oncology Group (ECOG) score \[0-1\] points; 5. The expected survival period is ≥12 weeks; 6. The diagnosis of invasive carcinoma by histology or cytology; Estrogen receptor (ER) positive (defined as \>1% nuclear ER staining); HER2 negative (defined as IHC 0 or 1+, or HER2(2+) with HER2 FISH detection no amplification); 7. Inoperable or recurrent/metastatic breast cancer patients with aromatase inhibitor treatment failure; 8. In the state of disease progression before enrollment; 9. There are FGFR mutations, which meets any of the following: ①Immunohistochemical method: any subtype of FGFR1/2/3/4 is positive; ② Gene detection results of tissue/blood sample shows that any subtype of FGFR1/2/3/4 has functional variation such as amplification, activating mutation or fusion; 10. Measurable disease according to RECIST version 1.1 or only bone metastasis; 11. Adequate hematological, hepatic function; 12. Doppler ultrasound: left ventricular ejection fraction (LVEF) ≥50%. Exclusion Criteria: 1. Have used Fulvestrant or its analogues; 2. History of other primary malignancy; 3. Allergic to the ingredients of Anlotinib Hydrochloride Capsules; 4. Previously received targeted drug therapy for FGFR; 5. Received chemotherapy within 4 weeks before enrollment; 6. Received endocrine therapy within 2 weeks before enrollment; 7. Patients with currently symptomatic brain or meningeal metastasis; 8. Concomitant diseases/conditions that is not controllable, and any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the patient's participation in this study; 9. Patients who cannot accept drugs orally; 10. Any other situation that the investigator judges cannot be enrolled in the study.